• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

KidsAP

  • Home
  • Project Overview
  • Clinical Studies
    • KidsAP01
    • KidsAP02
  • Consortium
  • News
    • Publications
  • Contact
  • Kid’s Section

Project Overview

Overview

The purpose of the KidsAP project is to assess the ability of the artificial pancreas to improve glucose control in the most vulnerable population with type 1 diabetes, children aged 1 to 7 years.

Overall Objective

The KidsAP objective is to compare the biomedical, psychological and health economics effectiveness of two insulin delivery systems in young children aged 1 to 7 years with type 1 diabetes. The insulin delivery systems are:

Closed Loop (Artificial Pancreas) insulin delivery (novel investigational personalised algorithmic insulin delivery below and above preset insulin amounts to avoid hypo and hyperglycaemia)

Sensor augmented pump therapy (state-of-the-art comparator)

Objectives

KidsAP01
Primary Objective Time spent in target glucose range 3.9 to 10mmol/l (70 to 180 mg/dl)
Secondary Objectives

 

 

1. To redefine the recruitment pathways to optimise recruitment to the outcome trial

2. To open contingency sites if recruitment targets are not met in the feasibility pilot

3. To pilot regulatory submissions to national regulatory bodies for approval of closed loop insulin delivery system in children

KidsAP02
Primary Objective Between group difference in time spent with sensor glucose levels between 3.9 to 10.0mmol/l (70 to 180mg/dl) during the 4 months intervention period.
Key Secondary Objectives Efficacy: To assess the ability of a hybrid closed loop system to maintain CGM glucose levels within the target range of 3.9 to 10 mmol/l (70 to 180 mg/dl) in comparison with sensor augmented pump therapy in very young children with type 1 diabetes.

Safety: To evaluate the safety of closed loop glucose control compared with sensor augmented pump therapy in terms of episodes and severity of hypoglycaemia, frequency of diabetic ketoacidosis (DKA) and nature and severity of other adverse events.

Utility: To determine the acceptability and duration of use of the closed loop system in this population

Human Factors: To assess emotional and behavioural characteristics of participants and parents/guardians and their response to the closed loop system and clinical trial using validated surveys and semi-structured qualitative interviews

Health Economics: To perform a cost utility analysis to inform reimbursement decision-making

Work Packages

Work Package 1 – Project Management

WP1 will address project coordination and management. The main objectives are to coordinate, manage and monitor the project, to ensure swift and smooth decision making, communication within the consortium and towards the Commission and to report to the Commission. It will foster collaboration between the Participants and ensure compliance with EC requirements.

Work Package 2 – Pilot Study

WP2 will perform a feasibility trial to pilot the study setup and to address the specific needs of the studied population by comparing closed loop insulin delivery using standard strength insulin and diluted insulin over 3 weeks. The results will feed into the design of the main study.

Work Package 3 – Main Study

WP3 covers studying the application of the closed loop system at home, under daily life conditions in very young children with type 1 diabetes two 4-month periods.

To this goal, a randomised, multicentre, 2-period, cross over study will compare the use of the closed loop system to sensor augmented pump therapy. As determined by the pilot study, full strength will be used unless the participant is already using diluted insulin as part of their standard care.

The aim is to show effectiveness, safety and usability of the closed loop insulin delivery system, as well as its impact on children/family centred outcomes.

Work Package 4 – Data Management and Analysis

WP4 will integrate project specific data types in cooperation with all participants to ensure highest quality standards for clinical trial data management and subsequent data analysis.

WP4 will

  • provide a database for all KidsAP participants to share and access data and data analysis results as well as track progress
  • Manage all KidsAP data according to data safety and security regulations
  • Perform data analysis using state-of-the-art techniques to ensure maximum use of all gathered data

Work Package 5 – Health Economic Evaluation

The objective of WP5 is health economic analysis of the artificial pancreas (closed loop) versus conventional insulin pump therapy using a health economic simulation model: the IMS CORE DIABETES MODEL (CDM)

Work Package 6 – Dissemination and exploitation

WP6 encompasses various dissemination and exploitation activities, all focused to ensure effective and wide impact and visibility on different levels but also to avoid any overlap of efforts with similar research projects. All project results will be distributed to end users and external stakeholders to ensure maximal exploitation even after the end of KidsAP. WP6 will set up the framework to implement and execute the project’s dissemination and exploitation strategy, with the following objectives:

  • consider the commercial exploitation of study results
  • disseminate all scientific and technological results throughout the project to the scientific/technical/medical community
  • publically dissemination KidsAP’s progress and results to diabetes patients and patient organisations
  • design and implement an effective exploitation strategy

Work Package 7 – Ethics requirements

The objective is to ensure compliance with the “ethics requirements” set out within the work package.

Organisational Structure

The ambitious objectives of KidsAP require a strong and coherent management structure to support the progress of the project. The schematic to the right shows how the organisational bodies interact in the project.

 

Primary Sidebar

Tweets by _RomanHovorka

Advanced Technologies & Treatments for Diabetes (ATTD) 2022

…

Continue Reading

KidsAP02 Study Results

We are delighted to share that the KidsAP02 study has now been published! A study summary has been shared on the …

Continue Reading

Fourth Annual Consortium Meeting

This year due to the COVID-19 pandemic the annual consortium meeting was hosted virtually; the meeting aimed to share each of …

Continue Reading

​

The artificial pancreas in very young children with type 1 diabetes, a H2020 European Commission funded project

Recent Posts

  • Advanced Technologies & Treatments for Diabetes (ATTD) 2022
  • KidsAP02 Study Results
  • Fourth Annual Consortium Meeting
  • Recruitment has been completed!
  • Third Annual Consortium Meeting

Recent Comments

    Archives

    • May 2022
    • January 2022
    • August 2021
    • October 2020
    • January 2019
    • March 2018
    • January 2018
    • July 2017
    • June 2017

    Categories

    • News
    • Uncategorised

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Footer

     

    This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 731560.
    The Jaeb Center for Health Research is funded by JDRF under the grant 3-SRA-2016-297-M-N.
    Disclaimer  

     

     

    Copyright © 2023  .  Hosted by CSCS

    Copyright © 2023 · Maker Pro on Genesis Framework · WordPress · Log in